{"id":18843,"date":"2024-05-26T20:59:22","date_gmt":"2024-05-26T18:59:22","guid":{"rendered":"https:\/\/tirzepatyd.eu\/?post_type=product&p=18843"},"modified":"2026-04-19T11:19:58","modified_gmt":"2026-04-19T09:19:58","slug":"glp-3-retatrutid-4mg-injekcni-lahvicka","status":"publish","type":"product","link":"https:\/\/tirzepatyd.eu\/cs\/obchod-produkt\/glp-3-retatrutid-4mg-injekcni-lahvicka\/","title":{"rendered":"Triple G 4 mg injek\u010dn\u00ed lahvi\u010dka GLP3"},"content":{"rendered":"
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

GLP-3 Retatrutid - co to je?<\/h2>

GLP-3 Retatrutid je syntetick\u00fd v\u00fdzkumn\u00fd peptid vyvinut\u00fd jako nov\u00fd agonista v\u00edce receptor\u016f. Jeho struktura je zalo\u017eena na \u0159et\u011bzci aminokyselin (p\u0159ibli\u017en\u011b 39-41 aminokyselin), kter\u00fd je navr\u017een tak, aby sou\u010dasn\u011b aktivoval receptory GLP-1, GIP a glukagonu. Tato kombinace mechanism\u016f se prom\u00edt\u00e1 do v\u00edcesm\u011brn\u00e9 \u00fa\u010dinky na regulaci chuti k j\u00eddlu, energetick\u00fd metabolismus a metabolismus gluk\u00f3zy.<\/strong>, co\u017e z retatrutidu \u010din\u00ed obzvl\u00e1\u0161t\u011b slibnou l\u00e1tku v souvislosti s l\u00e9\u010dbou obezity. Struktura molekuly obsahuje modifikace pro zv\u00fd\u0161en\u00ed metabolick\u00e9 stability, v\u010detn\u011b p\u0159ipojen\u00ed lipidov\u00e9ho \u0159et\u011bzce, kter\u00fd umo\u017e\u0148uje vazbu na albumin a prodlu\u017euje dobu p\u016fsoben\u00ed l\u00e9\u010diva v organismu, \u010d\u00edm\u017e podporuje pohodln\u00e9 pou\u017e\u00edv\u00e1n\u00ed a dlouhotrvaj\u00edc\u00ed \u00fa\u010dinek na sn\u00ed\u017een\u00ed hmotnosti<\/strong>. Stejn\u011b jako Semaglutid<\/a> i Tirzepatid<\/a>, retatrutid pat\u0159\u00ed do skupiny agonist\u016f inkretinov\u00fdch receptor\u016f pou\u017e\u00edvan\u00fdch ve v\u00fdzkumu pro l\u00e9\u010dbu obezity a metabolick\u00fdch poruch.<\/span><\/p>

GLP-3 Retatrutid je peptid vyv\u00edjen\u00fd pro l\u00e9\u010dbu obezity a diabetu 2. typu. <\/span>Jedn\u00e1 se o typ agonisty receptor\u016f GLP-1, GIP a glukagonu. <\/b>P\u016fsob\u00ed na r\u016fzn\u00e9 biologick\u00e9 mechanismy, kter\u00e9 reguluj\u00ed chu\u0165 k j\u00eddlu, metabolismus gluk\u00f3zy a sekreci inzul\u00ednu. P\u0159edev\u0161\u00edm d\u00edky tomu je \u00fa\u010dinn\u00fd p\u0159i sni\u017eov\u00e1n\u00ed hmotnosti a kontrole hladiny cukru v krvi. Na rozd\u00edl od jin\u00fdch peptid\u016f tohoto typu p\u0159\u00edpravek vykazuje je\u0161t\u011b \u00fa\u010dinn\u011bj\u0161\u00ed p\u016fsoben\u00ed sm\u011brem k hubnut\u00ed.\u00a0<\/span><\/p>

Viz tak\u00e9 Orforglipron GLP1 \u010dinidlo v kapsl\u00edch 5mg\/60caps<\/a><\/p>

GLP-3 Retatrutid<\/b> a v\u00fdzkumu obezity?<\/b><\/h2>

GLP-3 Retatrutid<\/b> je nov\u00fd peptid testov\u00e1no pro l\u00e9\u010dbu obezity<\/a>. P\u016fsob\u00ed tak, \u017ee sou\u010dasn\u011b ovliv\u0148uje n\u011bkolik hormon\u00e1ln\u00edch receptor\u016f v t\u011ble, \u010d\u00edm\u017e se li\u0161\u00ed od mnoha jin\u00fdch p\u0159\u00edpravk\u016f na obezitu. Zde je uvedeno, jak ovliv\u0148uje t\u011blo:<\/span><\/p>

  1. GLP-1 (glukagonu podobn\u00fd peptid-1). <\/b>Nejprve sthymuluje sekreci inzul\u00ednu a inhibuje sekreci glukagonu, co\u017e n\u00e1sledn\u011b pom\u00e1h\u00e1 regulovat hladinu cukru v krvi. Krom\u011b toho ovliv\u0148uje centrum sytosti v mozku, \u010d\u00edm\u017e sni\u017euje chu\u0165 k j\u00eddlu.<\/span><\/li>
  2. GIP (gluk\u00f3zo-dependentn\u00ed inzulinotropn\u00ed polypeptid).\u00a0<\/b>Pom\u00e1h\u00e1 zvy\u0161ovat sekreci inzulinu po konzumaci j\u00eddla, co\u017e tak\u00e9 pom\u00e1h\u00e1 kontrolovat hladinu gluk\u00f3zy v krvi. V kombinaci s GLP-1 synergicky zvy\u0161uje \u00fa\u010dinky na hubnut\u00ed.<\/span><\/li>
  3. Glukagonov\u00fd receptor.\u00a0<\/b>Stimulace tohoto receptoru pom\u00e1h\u00e1 zv\u00fd\u0161it energetick\u00fd v\u00fddej organismu, co\u017e podporuje hubnut\u00ed.<\/span><\/li><\/ol>

    GLP-3 je tedy multifunk\u010dn\u00ed peptid, kter\u00fd sou\u010dasn\u011b p\u016fsob\u00ed na n\u011bkolik mechanism\u016f reguluj\u00edc\u00edch metabolismus, chu\u0165 k j\u00eddlu a v\u00fddej energie. Tento holistick\u00fd p\u0159\u00edstup m\u016f\u017ee n\u00e1sledn\u011b v\u00e9st k \u00fa\u010dinn\u011bj\u0161\u00ed a trvalej\u0161\u00ed l\u00e9\u010db\u011b obezity ve srovn\u00e1n\u00ed s l\u00e9ky p\u016fsob\u00edc\u00edmi na jednotliv\u00e9 oblasti souvisej\u00edc\u00ed s metabolismem.<\/span><\/p>

    Pod\u00edvejte se tak\u00e9 na \u010dinidlo Retatrutid GLP3 PEN<\/a><\/p>

    GLP-3 Retatrutid - pozorov\u00e1n\u00ed z v\u00fdzkumn\u00fdch studi\u00ed<\/h2>

    Dostupn\u00e9 na publikace<\/a> v\u011bdeck\u00e9 a analytick\u00e9 \u00fadaje z preklinick\u00fdch a klinick\u00fdch studi\u00ed ukazuj\u00ed, \u017ee retatrutid jako trojit\u00fd agonista receptor\u016f GLP-1, GIP a glukagonu vykazuje \u0159adu biologick\u00fdch vlastnost\u00ed d\u016fle\u017eit\u00fdch pro studium regulace metabolismu a energetick\u00e9 rovnov\u00e1hy. N\u00ed\u017ee jsou shrnuta hlavn\u00ed pozorov\u00e1n\u00ed uveden\u00e1 ve v\u011bdeck\u00e9 literatu\u0159e.<\/p>

    Zm\u011bny t\u011blesn\u00e9 hmotnosti u studovan\u00fdch populac\u00ed<\/strong><\/p>

    V klinick\u00fdch studi\u00edch prov\u00e1d\u011bn\u00fdch s retatrutidem byly pozorov\u00e1ny v\u00fdznamn\u00e9 zm\u011bny t\u011blesn\u00e9 hmotnosti, zejm\u00e9na u skupin, kter\u00e9 dost\u00e1valy vy\u0161\u0161\u00ed studijn\u00ed d\u00e1vky. Podle anal\u00fdzy klinick\u00fdch \u00fadaj\u016f popsan\u00fdch v \u010dl\u00e1nku Medscape (n\u011bmeck\u00e9 vyd\u00e1n\u00ed) bylo u vybran\u00fdch studijn\u00edch populac\u00ed zaznamen\u00e1no pr\u016fm\u011brn\u00e9 sn\u00ed\u017een\u00ed hmotnosti dosahuj\u00edc\u00ed p\u0159ibli\u017en\u011b 20-25% po dobu sledov\u00e1n\u00ed a\u017e 48 t\u00fddn\u016f. Tyto v\u00fdsledky odli\u0161ily retatrutid od ostatn\u00edch inkretinov\u00fdch agonist\u016f a byly p\u0159edm\u011btem rozs\u00e1hl\u00fdch srovn\u00e1vac\u00edch anal\u00fdz v odborn\u00e9 literatu\u0159e.<\/p>

    \u00da\u010dinky na metabolismus gluk\u00f3zy<\/strong><\/p>

    Aktivace receptor\u016f GLP-1 a GIP je spojena se zlep\u0161en\u00edm parametr\u016f kontroly glyk\u00e9mie pozorovan\u00fdm ve studi\u00edch. Mechanismus zahrnuje na gluk\u00f3ze z\u00e1vislou modulaci sekrece inzulinu a sn\u00ed\u017een\u00ed nadm\u011brn\u00e9 sekrece glukagonu. v \u010dl\u00e1nku Medscape se zd\u016fraz\u0148uje, \u017ee retatrutid vykazoval v\u00fdznamn\u00e9 \u00fa\u010dinky na metabolick\u00e9 parametry souvisej\u00edc\u00ed s metabolismem gluk\u00f3zy, co\u017e bylo pozorov\u00e1no soub\u011b\u017en\u011b se zm\u011bnami t\u011blesn\u00e9 hmotnosti ve studovan\u00fdch kohort\u00e1ch.<\/p>

    Modulace mechanism\u016f reguluj\u00edc\u00edch chu\u0165 k j\u00eddlu<\/strong><\/p>

    Na v\u00fdzkumn\u00fdch modelech byly pops\u00e1ny \u00fa\u010dinky retatrutidu na centr\u00e1ln\u00ed dr\u00e1hy sytosti, kter\u00e9 vedou ke sn\u00ed\u017een\u00ed p\u0159\u00edvodu energie. Tento jev p\u0159edstavuje d\u016fle\u017eitou oblast v\u00fdzkumu neurohormon\u00e1ln\u00ed regulace chuti k j\u00eddlu. Z anal\u00fdzy spole\u010dnosti Medscape vypl\u00fdv\u00e1, \u017ee sou\u010dasn\u00e1 aktivace n\u011bkolika hormon\u00e1ln\u00edch receptor\u016f.<\/strong> m\u016f\u017ee b\u00fdt zodpov\u011bdn\u00fd za komplexn\u011bj\u0161\u00ed \u00fa\u010dinek na regulaci chuti k j\u00eddlu ve srovn\u00e1n\u00ed s agonisty s jedn\u00edm nebo dv\u011bma receptory.<\/p>

    Zm\u011bny metabolick\u00fdch parametr\u016f<\/strong><\/p>

    B\u011bhem studie byly analyzov\u00e1ny i dal\u0161\u00ed metabolick\u00e9 ukazatele, jako je lipidov\u00fd profil, krevn\u00ed tlak a vybran\u00e9 markery kardiovaskul\u00e1rn\u00edho rizika. V publikac\u00edch citovan\u00fdch serverem Medscape byly zaznamen\u00e1ny p\u0159\u00edzniv\u00e9 trendy v n\u011bkter\u00fdch metabolick\u00fdch parametrech, auto\u0159i v\u0161ak zd\u016fraz\u0148uj\u00ed, \u017ee k \u00fapln\u00e9mu vyhodnocen\u00ed t\u011bchto pozorov\u00e1n\u00ed je t\u0159eba prov\u00e9st dal\u0161\u00ed dlouhodob\u00e9 studie.<\/p>

    Vliv na energetick\u00fd v\u00fddej<\/strong><\/p>

    Stimulace glukagonov\u00fdch receptor\u016f, kter\u00e1 je sou\u010d\u00e1st\u00ed trojit\u00e9ho mechanismu \u00fa\u010dinku retatrutidu, je spojena se zv\u00fd\u0161en\u00fdm energetick\u00fdm v\u00fddejem a mobilizac\u00ed energetick\u00fdch substr\u00e1t\u016f. Tento mechanismus p\u0159edstavuje d\u016fle\u017eitou oblast v\u00fdzkumu energetick\u00e9 rovnov\u00e1hy a metabolick\u00e9 adaptace. \u010cl\u00e1nek v Medscape zd\u016fraz\u0148uje, \u017ee agonistick\u00e1 slo\u017eka glukagonov\u00e9ho receptoru<\/strong> m\u016f\u017ee hr\u00e1t d\u016fle\u017eitou roli v pozorovan\u00fdch metabolick\u00fdch zm\u011bn\u00e1ch, \u010d\u00edm\u017e se retatrutid odli\u0161uje od klasick\u00fdch inkretinov\u00fdch agonist\u016f.<\/p>

    GLP-3 Retatrutid - shrnut\u00ed<\/h3>

    Retatrutid (LY3437943) je syntetick\u00fd peptid, kter\u00fd je trojit\u00fdm agonistou receptor\u016f GLP-1, GIP a glukagonu a je p\u0159edm\u011btem preklinick\u00fdch a klinick\u00fdch studi\u00ed v oblasti energetick\u00e9ho metabolismu a regulace gluk\u00f3zy. Tato slou\u010denina vykazuje v\u00edcesm\u011brn\u00e9 \u00fa\u010dinky na mechanismy reguluj\u00edc\u00ed energetickou rovnov\u00e1hu, chu\u0165 k j\u00eddlu a metabolismus gluk\u00f3zy, co\u017e se odr\u00e1\u017e\u00ed v pozorov\u00e1n\u00edch uveden\u00fdch ve v\u011bdeck\u00e9 literatu\u0159e. Jeho farmakodynamick\u00fd profil, kter\u00fd je v\u00fdsledkem struktur\u00e1ln\u00edch modifikac\u00ed, \u010din\u00ed z retatrutidu d\u016fle\u017eit\u00fd c\u00edl pro studium komplexn\u00edch inkretinov\u00fdch drah.<\/p>

    \"GLP-3<\/a><\/p>

    Zdroj:<\/a><\/p>

    V\u00fdrobek je ur\u010den pro v\u011bdeck\u00fd v\u00fdzkum a laboratorn\u00ed anal\u00fdzy. V\u0161echny \u010dl\u00e1nky a informace na t\u011bchto webov\u00fdch str\u00e1nk\u00e1ch slou\u017e\u00ed pouze k informa\u010dn\u00edm a vzd\u011bl\u00e1vac\u00edm \u00fa\u010del\u016fm.<\/strong><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"

    Retatrutid je v\u00fdzkumn\u00fd peptid nov\u00e9 generace spojen\u00fd s procesy ovliv\u0148uj\u00edc\u00edmi chu\u0165 k j\u00eddlu, rychlost metabolismu a energetickou rovnov\u00e1hu v t\u011ble. D\u00edky sv\u00e9mu \u0161irok\u00e9mu spektru \u00fa\u010dink\u016f je \u010dasto vn\u00edm\u00e1n jako sou\u010d\u00e1st inovativn\u00edch koncept\u016f souvisej\u00edc\u00edch s kontrolou hmotnosti. Vynik\u00e1 sv\u00fdmi pokro\u010dil\u00fdmi vlastnostmi a modern\u00edm p\u0159\u00edstupem k metabolismu.<\/p>","protected":false},"featured_media":31137,"comment_status":"open","ping_status":"closed","template":"","meta":{"_acf_changed":false},"product_brand":[],"product_cat":[124,109,15],"product_tag":[136],"class_list":["post-18843","product","type-product","status-publish","has-post-thumbnail","product_cat-produkty-w-fiolce","product_cat-triple-g","product_cat-laboratory-research","product_tag-fiolka","first","instock","shipping-taxable","purchasable","product-type-variable"],"acf":[],"aioseo_notices":[],"aioseo_head":"\n\t\t\n\t\n\t\n\t\n\t\n\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t